Evidence map›Paper›PMID 37148788›Full record

ArticleBioorganic & medicinal chemistry2023

Structure-Activity relationships of replacements for the triazolopyridazine of Anti-Cryptosporidium lead SLU-2633.

Edmund Oboh, José E Teixeira, Tanner J Schubert, Adriana S Maribona, Brylon N Denman, Radhika Patel, Christopher D Huston, Marvin J Meyers

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bioorganic & medicinal chemistry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.7field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 6 citations in OpenAlex.

  1. Discovery of an Orally Efficacious Pyrazolo[3,4-Journal of medicinal chemistry · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Edmund ObohDepartment of Chemistry, School of Science and Engineering, Saint Louis University, Saint Louis, MO 63103, United States.
José E TeixeiraDepartment of Medicine, University of Vermont Larner College of Medicine, Burlington, VT 05401, United States.
Tanner J SchubertDepartment of Chemistry, School of Science and Engineering, Saint Louis University, Saint Louis, MO 63103, United States.
Adriana S MaribonaDepartment of Chemistry, School of Science and Engineering, Saint Louis University, Saint Louis, MO 63103, United States.
Brylon N DenmanDepartment of Chemistry, School of Science and Engineering, Saint Louis University, Saint Louis, MO 63103, United States.
Radhika PatelDepartment of Chemistry, School of Science and Engineering, Saint Louis University, Saint Louis, MO 63103, United States.
Christopher D HustonDepartment of Medicine, University of Vermont Larner College of Medicine, Burlington, VT 05401, United States. Electronic address: christopher.huston@uvm.edu.
Marvin J MeyersDepartment of Chemistry, School of Science and Engineering, Saint Louis University, Saint Louis, MO 63103, United States; Institute for Drug and Biotherapeutic Innovation, Saint Louis University, St. Louis, MO 63103, United States. Electronic address: marvin.j.meyers@slu.edu.
Saint Louis University · USUniversity of Vermont · USSaint Louis University · ES

Funding

Preclinical optimization of a parasiticidal drug for cryptosporidiosisR01AI143951 · NIAID · UNIVERSITY OF VERMONT & ST AGRIC COLLEGE · PI HUSTON, CHRISTOPHER D, MEYERS, MARVIN J · 2019 to 2023
$3.3M
NIAID NIH HHS R01 AI143951
6 · The paper itself

Abstract

Cryptosporidiosis is a diarrheal disease particularly harmful to children and immunocompromised people. Infection is caused by the parasite Cryptosporidium and leads to dehydration, malnutrition, and death in severe cases. Nitazoxanide is the only FDA approved drug but is only modestly effective in children and ineffective in immunocompromised patients. To address this unmet medical need, we previously identified triazolopyridazine SLU-2633 as potent against Cryptosporidium parvum, with an EC

Indexed as

Antiprotozoal AgentsCryptosporidiumChildHumansNitro CompoundsPyridazinesStructure-Activity RelationshipThiazolesTriazoles7,8-dihydro-(1,2,4)triazolo(4,3-b)pyridazineAntiprotozoal AgentsnitazoxanideNitro CompoundsPyridazinesSLU-2633ThiazolesTriazoles[1, 2, 4]triazolo[4, 3-b]pyridazineAnticryptosporidialAntiparasiticCryptosporidiosisCryptosporidiumDiarrheahERGSLU-2633Triazolopyridazine

Identifiers

PMID37148788
PMCPMC10201403
OpenAlexW4367297302

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.